LEADER 01750oam  2200421   450 
001 9910708458003321
005 20170327124208.0
035   $a(CKB)3460000000105421
035   $a(OCoLC)941346244
035   $a(EXLCZ)993460000000105421
100   $a20160226d2004      ua             0
101 0 $aeng
135   $aurbn||||a||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aAvoiding conflicts of interest at the National Institutes of Health $ehearing before a subcommittee of the Committee on Appropriations, United States Senate, One Hundred Eighth Congress, second session, special hearing, January 22, 2004, Washington, DC
210  1$aWashington :$cU.S. Government Printing Office :$cFor sale by the Superintendent of Documents, U.S. Government Printing Office,$d2004.
215   $a1 online resource (iii, 61 pages)
225 1 $aS. hrg. ;$v108-710
300   $a"Printed for the use of the Committee on Appropriations."
300   $aDistributed to some depository libraries in microfiche.
517   $aAvoiding conflicts of interest at the National Institutes of Health 
606   $aConflict of interests$zUnited States
606   $aScientists in government$xProfessional ethics$zUnited States
606   $aPharmaceutical industry$zUnited States
608   $aLegislative hearings.$2lcgft
615  0$aConflict of interests
615  0$aScientists in government$xProfessional ethics
615  0$aPharmaceutical industry
801  0$bOCLCE
801  1$bOCLCE
801  2$bOCLCQ
801  2$bGPO
906   $aBOOK
912   $a9910708458003321
996   $aAvoiding conflicts of interest at the National Institutes of Health$93440083
997   $aUNINA